Biotechnology company Genzyme Corp. said its profit shrank drastically in the second quarter because of falling sales and charges partly connected to its manufacturing problems.
Pharmaceuticals maker Roche Holding AG posted a 37 percent rise in six-month net profit on strong drug sales and lower costs related to its takeover of U.S.-based Genentech.
Eli Lilly and Co. said its second-quarter net income soared 16%, boosted in part by revenue growth from key drugs that face patent expirations in the coming years.
Federal health officials are barring new patients from enrolling in a safety study of GlaxoSmithKline's controversial diabetes pill Avandia, a week after a panel of experts ruled that the drug increases heart risks.
A dozen recent federal inspections of a Johnson & Johnson factory for heartburn and other nonprescription medicines show a host of violations that could affect the quality and makeup of the drugs.
In an effort to better serve its readers, Drug Discovery & Development has enhanced its e-newsletter distribution system. To ensure that you continue to receive prompt delivery of DDD Update, please update your spam filters and add mail.dddmag.com to your safe sender list.
Labtronics Inc., a world leader in laboratory automation has released a Connector for Nexxis ELN that allows the Electronic Laboratory Notebook to connect to any LIMS.
Affymetrix, Inc. announced the launch of QuantiGene ViewRNA Assay formats, which enable a new era of “in situ multiplex gene expression analysis” by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies.
Ricerca Biosciences, LLC, a uniquely integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, has announced its innovative similarity analysis service, Foresight.
Eli Lilly and Company announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, announced initiation of a Phase 2 clinical trial of hGH-CTP, the company’s proprietary biobetter version of human growth hormone (hGH).
NovaBay Pharmaceuticals, Inc. announced results from a Phase 2a trial that show its lead product candidate is safe and efficacious against the highly contagious skin infection impetigo, including those infections caused by drug-resistant MRSA.
A long-standing question in bone biology has been answered: It is the spindly extensions of bone cells that sense mechanical stimulation and signal the release of bone-growth factors.
If mice are administered an antibiotic for three days and are simultaneously infected with malaria, no parasites appear in the blood and life-threatening disease is averted. In addition, the animals treated in this manner also develop robust, long-term immunity against subsequent infections.
Implanting tiny plastic scaffolds seeded with genetically engineered stem cells reduced organ damage and led to better cardiac function after a heart attack, according to a recent animal study.